Saturday, May 31, 2025

Latest

Psyched Wellness Commences 90-Day Toxicity Study Of AME-1

Psyched Wellness (CSE: PSYC) continues to progress on its preclinical studies for its novel mushroom extract formulation. The company this morning announced that it has begun on the latest preclinical study, which focuses on oral toxicity.

Research on the formulation, which is an extract of the Amanita Muscaria mushroom and referred to as AME-1, is being conducted by the firms contract research organization, KGK Science. The firm is now focused on a 90 day toxicity study as it works to receive pre-clinical approvals for its novel formulation.

The new study follows a 14-day toxicity study previously conducted, and will be performed on rodents. Test subjects are to receive a repeated dose of the extract over the test period. The study will look to identify anatomical responses from exposure over time, and cover maturation and growth into adulthood of the subjects to provide data on major toxic effects, accumulation of the test chemical, indicate the target organs, and finally provide an estimate of a no-observed-adverse-effect level, also known as NOAEL. The data will then be used to select dosage levels and esablish safety criteria for human exposure.

“The data from these studies will provide Psyched with the foundational knowledge from which all of our consumer products will be derived. This is a very exciting time for the Company, as we look forward to sharing the data from these studies in the near future and continuing to execute on our near- and long-term business objectives.”

Jeff Stevens, CEO

Psyched Wellness last traded at $0.205 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

G Mining Q1 Earnings: Bumps in the Road, But Still on Track

Endeavour Silver Q1 Earnings: Terronera Remains The Focus

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

Psyched Wellness Sees Positive Initial Results From AME-1 Extract Study

Psyched Wellness (CSE: PSYC) this morning provided an update on its study to determine the...

Thursday, February 4, 2021, 07:33:40 AM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM

Psyched Wellness To Conduct Stability Tests On Proprietary Mushroom Extract

Psyched Wellness (CSE: PSYC) is progressing with the development of its flagship product, an extract...

Monday, July 26, 2021, 09:28:00 AM

Psyched Wellness Attracts Major Investment

Jeffrey Stevens, CEO & Director of Psyched Wellness (CSE: PSYC) joins us in today’s episode...

Friday, June 9, 2023, 01:30:00 PM

Psyched Wellness Submits Trademark For Amanita Muscaria Extract

Psyched Wellness (CSE: PSYC) is looking to build up its portfolio of intellectual property. The...

Thursday, January 21, 2021, 07:01:48 AM